Biotech behind 2022’s largest local IPO delays norovirus vaccine


HilleVax Inc., the biotech that pulled off Boston's largest IPO of 2022, is delaying its norovirus vaccine by several months. CEO Rob Hershbeg cited logistical issues as reason for the delay.

Previous Exclusive: Lendlease halts work on $1B S.F. mixed-use tower again, this time citing market conditions
Next Definitive Healthcare acquires Populi for $52 million